• CervoMed flagged five AAIC 2026 presentations on neflamapimod in dementia with Lewy bodies, including Phase 2 exploratory efficacy and biomarker analyses.
• Updates include MRI data on basal forebrain atrophy as a potential disease-progression biomarker from the RewinD-LB Phase 2 trial.
• Company will also present first clinical results from a 24-week open-label Phase 2 study of neflamapimod 80 mg twice daily.
• AAIC runs July 12-15 in London; no regulatory approvals or pivotal-trial starts were announced.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief on July 06, 2026, and is solely responsible for the information contained therein.